TSHA · NASDAQ · Biotechnology

Taysha Gene Therapies (TSHA)

Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.

$5.28
After-hours close+0.13 (+2.45%)
At close$5.16(+2.28%)